Tempus AI Inc (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence to clinical and molecular data to support diagnostic and research decisions in oncology and cardiology. It makes money through two primary activities: performing Next Generation Sequencing (NGS) and other diagnostic tests ordered by healthcare institutions, and licensing de-identified clinical and molecular data to life sciences customers. The Tempus Platform connects more than 5,000 healthcare institution sites through more than 700 unique data connections, aggregating multimodal data including genomic, pathology, and clinical records into a unified database (as of the 10-K filed 2026-02-24). Products include Intelligent Diagnostics, the Next AI platform for oncology and cardiology care-gap identification, and a suite of algorithmic diagnostics under the Algos brand, covering tumor origin (TO), homologous recombination deficiency (HRD), DPYD, and Tempus Purist, among others. The company operates primarily in the United States, with oncology as its primary deployed market.

Revenue model

Revenue comes from diagnostic testing services, primarily NGS performed as a covered entity or business associate on behalf of healthcare institutions, and from licensing de-identified clinical and molecular data to life sciences companies. A limited number of paid license agreements with healthcare associations and institutions also contribute data acquisition and monetization activity.

Products and services

Tempus Platform (multimodal data aggregation and AI operating system); Intelligent Diagnostics (AI-augmented genomic and clinical test reports); Next AI platform (care-gap identification for oncology and cardiology); Algos suite (algorithmic diagnostics including TO, HRD, DPYD, and Tempus Purist); clinical trial matching services; data de-identification and structuring services.

Customers and end markets

Healthcare institutions (physicians and hospital systems ordering diagnostic tests); life sciences companies and researchers (data licensing and clinical trial support); oncology is the primary end market, with cardiology as an additional target. More than 5,000 healthcare institution sites order products and services as of the 10-K filed 2026-02-24.

Value-chain role

Diagnostic laboratory and AI data platform sitting between healthcare providers and life sciences companies. Collects multimodal clinical and molecular data from providers, structures and harmonizes it, performs or augments diagnostic testing, and licenses the resulting de-identified dataset to researchers and biopharma customers.

Geographic exposure

Primarily United States. Oncology deployment in the U.S. is described as the primary scaled market, with other disease areas and geographies described as following (per 10-K filed 2026-02-24).

Source: SEC 10-K, filed 2026-02-24

Industry: Services-Computer Programming, Data Processing, Etc. Peers: Azenta Inc Bio Rad Laboratories Inc Bruker Corp Charles River Laboratories International Inc Medpace Holdings Inc Repligen Corp Sotera Health Co Thermo Fisher Scientific Inc Fortrea Holdings Inc